Authors: KHAN SA KANIS JA VASIKARAN S KLINE WF MATUSZEWSKI BK MCCLOSKEY EV BENETON MNC GERTZ BJ SCIBERRAS DG HOLLAND SD ORGEE J COOMBES GM ROGERS SR PORRAS AG

Citation: Sa. Khan et al., ELIMINATION AND BIOCHEMICAL RESPONSES TO INTRAVENOUS ALENDRONATE IN POSTMENOPAUSAL OSTEOPOROSIS, Journal of bone and mineral research, 12(10), 1997, pp. 1700-1707

Authors: PETER CP GUY J SHEA M BAGDON W KLINE WF HAYES WC

Citation: Cp. Peter et al., LONG-TERM SAFETY OF THE AMINOBISPHOSPHONATE ALENDRONATE IN ADULT DOGS.1. GENERAL SAFETY AND BIOMECHANICAL PROPERTIES OF BONE, The Journal of pharmacology and experimental therapeutics, 276(1), 1996, pp. 271-276

Authors: GERTZ BJ HOLLAND SH KLINE WF MATUSZEWSKI BK FREEMAN A QUAN H LASSETER KC MUCKLOW JC PORRAS AG

Citation: Bj. Gertz et al., STUDIES OF THE ORAL BIOAVAILABILITY OF ALENDRONATE, Clinical pharmacology and therapeutics, 58(3), 1995, pp. 288-298

Authors: GERTZ BJ HOLLAND SD KLINE WF MATUSZEWSKI BK PORRAS AG

Citation: Bj. Gertz et al., CLINICAL-PHARMACOLOGY OF ALENDRONATE SODIUM, Osteoporosis international, 3, 1993, pp. 190000013-190000016